Amphotericin B: Is a Lipid-Formulation Gold Standard Feasible?

Spellberg, Brad; Witt, Mallory D.; Beck, C. Keith
January 2004
Clinical Infectious Diseases;1/15/2004, Vol. 38 Issue 2, p304
Academic Journal
Comments on the feasibility of amphotericin as a lipid formulation gold standard for treating mycoses. Replacement of amphotericin D deoxycholate by lipid-based formulations of amphotericin B; Description of the benefits of LFABs in relation to secondary, microbiological end points in clinical trials; Amount of sales of LFABs in the U.S.


Related Articles

  • Treatment of Invasive Fungal Infections - Up to now, and the future. Bennett, John E. // Japanese Journal of Medical Mycology;2008 Supplement 1, Vol. 49, p70 

    The article offers information on several treatments for invasive fungal infections, including amphotericin B, miconazole, oral clotrimazole, and voriconazole. Amphotericin B was put into practice in 1950s and proved to be potent in managing fungal infections. A decade after, miconazole and oral...

  • Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. Patterson, Thomas F.; Boucher, Helen W.; Herbrecht, Raoul; Denning, David W.; Lortholary, Olivier; Ribaud, Patricia; Rubin, Robert H.; Wingard, John R.; DePauw, Ben; Schlamm, Haran T.; Troke, Peter; Bennett, John E. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1448 

    Background. In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. In that trial, treatment with voriconazole or amphotericin B deoxycholate could be...

  • Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections: Results of the Collaborative Exchange of Antifungal Research (CLEAR), an Industry-Supported Patient Registry. Pappas, Peter G. // Clinical Infectious Diseases;5/1/2005 Supplement, Vol. 40, pS379 

    This article focuses on the use of amphotericin B lipid complex (ABLC) for the treatment of invasive fungal infections. ABLC is a composition of amphotericin B and 2 phospholipids, dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol, in a 1:1 drug-to-lipid molar ratio. ABLC was...

  • Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Walsh, Thomas J.; Anaissie, Elias J.; Denning, David W.; Herbrecht, Raoul; Kontoyiannis, Dimitrios P.; Marr, Kieren A.; Morrison, Vicki A.; Segal, Brahm H.; Steinbach, William J.; Stevens, David A.; van Burik, Jo-Anne; Wingard, John R.; Patterson, Thomas F. // Clinical Infectious Diseases;2/1/2008, Vol. 46 Issue 3, p327 

    The article focuses on the guidelines of the Infectious Diseases Society of America to treat the life-threatening infection aspergillosis. There are three major forms of aspergillosis including invasive aspergillosis, chronic forms of aspergillosis and allergic forms of aspergillosis. Based on...

  • Reply. Ostrosky-Zeichner, Luis; Marr, Kieren A.; Rex, John H.; Cohen, Stuart H. // Clinical Infectious Diseases;1/15/2004, Vol. 38 Issue 2, p306 

    Comments on the use of lipid formulations of amphotericin B in treating invasive fungal infections. Possibility of using continuous infusions of amphotericin B deoxycholate (AmBD); Limited comparative data supporting the efficacy of continuously infused AmBD; Link of short- and long-term...

  • Intralipid efficacy in decreasing Amphotericin B associated nephrotoxicity. Hasibi, Mehrdad; Jafari, Sirous; Khazraiyan, Hamideh; Ali Dehghan Manshadi, Seyed // Tehran University Medical Journal;Mar2013, Vol. 70 Issue 12, p774 

    Background: Amphotericin B Deoxycholate (ABD) has been the best therapeutic agent for treatment of most systemic fungal infections. However, untoward adverse effects like nephrotoxicity may limit its appropriate therapeutic use. We studied administration of fat emulsion early after infusion of...

  • Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. Strenger, Volker; Meinitzer, Andreas; Donnerer, Josef; Hofer, Nora; Dornbusch, Hans Jürgen; Wanz, Ulrike; Seidel, Markus G.; Sperl, Daniela; Lackner, Herwig; Schwinger, Wolfgang; Sovinz, Petra; Benesch, Martin; Urban, Christian // Journal of Antimicrobial Chemotherapy (JAC);Sep2014, Vol. 69 Issue 9, p2522 

    Objectives Although amphotericin B (AmB) and its lipid formulations are used for the treatment of fungal infections of the CNS, the kinetics of AmB in the CSF after intravenous administration of liposomal amphotericin B (LAmB) are not well characterized. Patients and methods From 14 paediatric...

  • Pharmacotherapy of Candida Infections with Echinocandins. Espinel-Ingroff, ,3Ana; Canton, Emilia; Martin-Mazuelos, Estrella; Pemán, Javier // Clinical Medicine: Therapeutics;2009, Issue 1, p889 

    The classic recommended antifungal agents for the treatment of invasive Candida infections were amphotericin B, a lipid formulation of amphotericin B and fluconazole in both neutropenic or nonneutropenic patients as either primary or alternative therapies. Voriconazole has been recommended when...

  • Treatment of Non-Aspergillus Moulds in Immunocompromised Patients, with Amphotericin B Lipid Complex. Perfect, John R. // Clinical Infectious Diseases;5/1/2005 Supplement, Vol. 40, pS401 

    An assessment was made of the efficacy and renal safety of amphotericin B lipid complex (ABLC) in the treatment of patients with invasive fungal infections caused by moulds other than Aspergillus species, on the basis of a retrospective analysis of data from the Collaborative Exchange of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics